← Back to Search

Computed Tomography Perfusion Imaging for Fallopian Tube Cancer

N/A
Waitlist Available
Led By Susanna Lee
Research Sponsored by ECOG-ACRIN Cancer Research Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time to progression or death from the t1 scan, assessed up to 18 months
Awards & highlights

Study Summary

This trial uses CT perfusion imaging to see how well a patient's tumor responds to bevacizumab treatment, which may help predict if the treatment will be successful.

Eligible Conditions
  • Fallopian Tube Cancer
  • Ovarian Cancer
  • Peritoneal Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time to progression or death from the t1 scan, assessed up to 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and time to progression or death from the t1 scan, assessed up to 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival (PFS)
Secondary outcome measures
Objective Response Rate

Side effects data

From 2018 Phase 2 trial • 22 Patients • NCT02101918
77%
Hypertension
68%
Headache
45%
Mucositis oral
41%
Hoarseness
32%
Proteinuria
27%
Fatigue
23%
Constipation
23%
Nausea
23%
Abdominal pain
23%
Vomiting
18%
Alanine aminotransferase increased
18%
Diarrhea
18%
Arthralgia
14%
Neutrophil count decreased
14%
Creatinine increased
14%
Anorexia
14%
Pain
14%
Palmar-plantar erythrodysesthesia syndrome
14%
Epistaxis
14%
Weight loss
14%
Aspartate aminotransferase increased
14%
Platelet count decreased
14%
Anemia
9%
Sinusitis
5%
Dehydration
5%
Upper gastrointestinal hemorrhage
5%
cholecystitis
5%
Hemorrhage Upper GI
5%
Pain Abdominal
100%
80%
60%
40%
20%
0%
Study treatment Arm
Aflibercept 6 mg /kg IV

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (computed tomography perfusion imaging)Experimental Treatment1 Intervention
Patients undergo computed tomography perfusion imaging at baseline and on day 15 after initiation of standard of care bevacizumab treatment and before the second dose.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography Perfusion Imaging
2016
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

ECOG-ACRIN Cancer Research GroupLead Sponsor
116 Previous Clinical Trials
176,921 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,662 Previous Clinical Trials
40,925,880 Total Patients Enrolled
Susanna LeePrincipal InvestigatorECOG-ACRIN Cancer Research Group

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab
2018. "Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03412630.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top